• 1
    Vahle J, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma YL, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone(1–34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312321.
  • 2
    Wiig JN, Sand Bakker T 1971 Hyperparathyroidism with multiple malignant tumors of bone with giant cells. Acta Chir Scand 137: 391393.
  • 3
    Smith J, Huvos AG, Chapman M, Rabbs C, Spiro RH 1997 Hyperparathyroidism associated with sarcoma of bone. Skeletal Radiol 26: 107112.
  • 4
    Betancourt M, Wirfel KL, Raymond AK, Yasko AW, Lee J, Vassilopoulou-Sellin R 2003 Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report. J Bone Miner Res 18: 163166.
  • 5
    Greenfield GB 1975 The solitary lesion. In: BurgowerW, PattersonD, HoeltzelLE (eds.) Radiology of Bone Diseases, 2nd ed. Lippincott Company, Philadelphia, p. 425.
  • 6
    Adami S, Marcocci C, Gatti D 2002 Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17: N18N23.
  • 7
    Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O'Fallon WM, Melton LJ III 1997 The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965–1992. Ann Intern Med 126: 433440.
  • 8
    Dorfman HD, Czerniak B 1995 Bone cancers. Cancer 75: 203210.
  • 9
    Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG, Bell RS, Juppner H, Andrulis IL, Wunder JS, Alman BA 2002 A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 30: 306310.
  • 10
    Pickard AL, Gridley G, Mellemkjae L, Johansen C, Kofoed-Enevoldsen A, Cantor KP, Brinton LA 2002 Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 95: 16111617.
  • 11
    Neer RM, Arnaud CD, Zancheta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 244: 14341441.
  • 12
    Tashian AH, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17: 11511161.
  • 13
    Vahle JL, Long GG, Sata M 2004 Dose and treatment duration are key factors in the development of bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)]. J Bone Miner Res (in press)
  • 14
    Jimenez C, Kim W, Al Sagier, El Nahhar A, Sellin R, Berry D, Gagel RF 2004 Primary hyperparathyroidism and osteosarcoma: Examination of a large osteosarcoma cohort identifies unique characteristics. J Bone Miner Res (in press)
  • 15
    Raskind WH, Conrad EU, Matsushita M 1996 Frequent loss of heterozygosity for markers on chromosome arm 10q in chondrosarcomas. Genes Chromosomes Cancer 16: 138143.
  • 16
    Oishi S, Sato T, Takiguchi-Shirahama S, Nakamura Y 1995 Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Endocr J 42: 527536.
  • 17
    Stratakis CA 2001 Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes. J Endocrinol Invest 24: 370383.
  • 18
    Pausova Z, Sliman E, Amizuka N 1996 Role of RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 81: 27112718.
  • 19
    Jenkins PJ, Satta MA, Simmgen M 1997 Metastatic parathyroid carcinoma in the MEN 2A syndrome. Clin Endocrinol (Oxf) 47: 747751.
  • 20
    Williams GH, Rooney S, Carss A, Cummins G, Thomas GA, Williams ED 1996 Analysis of the RET proto-oncogene in sporadic parathyroid adenomas. J Pathol 180: 138141.
  • 21
    Shattuck TM, Valimaki S, Obrar T, Gaz RD, Clark OH, Shoback D, Wierman ME, Too K, Robbins CM, Carpten JD, Farnebo L-O, Larsson C, Arnold A 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349: 17221729.